News Shionogi & Co., Ltd.

Stocks

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-06-12 EDT			5-day change	1st Jan Change
2,775.50 ^JPY	+0.22%		-3.12%	-2.31%

06-05	Shionogi & Co Ltd Announces New Product Launch of 'ENDEAVORRIDE'	CI
06-01	US regulator approves oral drug from Japan's Shionogi to prevent COVID-19	RE

All News

Mentions Relevance

06-05	Shionogi & Co Ltd Announces New Product Launch of 'ENDEAVORRIDE'	CI
06-01	US regulator approves oral drug from Japan's Shionogi to prevent COVID-19	RE
05-31	Shionogi & Co Secures US FDA Approval for Oral Antiviral to Prevent COVID-19 After Exposure	MT
05-31	Shionogi & Co., Ltd. Announces FDA Approval Of XOCOVA For Post-Exposure Prophylaxis Of COVID-19	CI
05-31	Shionogi Co Ltd - Shionogi's U.S. unit receives FDA approval for ensitrelvir as post-exposure prophylaxis for Covid-19	RE
05-31	Shionogi & Co., Ltd. Announces US FDA's Approval of the Anti-Coronavirus (SARS-CoV-2) Drug Encitrelvir Fumarate for Post-Exposure Prevention of Covid-19	CI
05-29	Shionogi & Co., Ltd.'s Group Company Shionogi China Co., Ltd. Receives Approval for Naldemedine for Opioid-Induced Constipation in China	CI
05-29	Shionogi Co: Shionogi China has received approval from NMPA of China for naldemedine, a treatment for opioid-induced constipation	RE
05-13	Shionogi Covid Pill Reduced Infection Risk in Late-Stage Study	MT
05-13	Shionogi & Co., Ltd. Announces Results from Its Global, Double-Blind, Randomized, Placebo-Controlled Phase 3 Study	CI
05-12	Shionogi : FY2025 Financial Results	PU
05-12	Shionogi : FY2025 Supplement	PU
05-12	Shionogi : FY2025 Financial Results	PU
05-12	Shionogi & Co., Ltd. Proposes Year End Dividend for the Year Ended March 31, 2026, Payable on June 25, 2026 and Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2027	CI
05-12	Shionogi & Co., Ltd. Provides Year-End Dividend Guidance for the Year Ending March 31, 2027	CI
05-12	Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and for the Year Ending March 31, 2027	CI
05-12	Shionogi & Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
04-27	Shionogi to Absorb Torii Pharmaceutical in April 2027 Merger	MT
04-14	Restore Vision Inc. announced that it has received ¥1.3 billion in funding from a group of investors	CI
04-08	Shionogi & Co receives contract with U.S. government through BARDA's Project BioShield to enhance national preparedness for drug-resistant bacterial threats	RE
04-07	Shionogi & Co., Ltd. Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja/Fetcroja (Cefiderocol) in Mbl-Producing Enterobacterales Infections	CI
04-02	Shionogi Completes $2.5 Billion RADICAVA Rights Acquisition	MT
04-01	Shionogi & Co: acquisition of all rights to Radicava (edaravone) is expected to be immediately accretive in fiscal year 2026, adding approximately USD $700 million in annual global sales	RE
03-31	ViiV Healthcare Limited announced that it has received $2.125 billion in funding from Shionogi & Co., Ltd.	CI
03-29	Final dividend	FA